Given the prevalence of BRAF and PTEN alterations in human melanoma, our results, which demonstrated that in vivo targeting of Loxl3 was deleterious to melanomagenesis in a mouse model harboring activated BrafV600E and loss of Pten, warrant future strategies aimed at blocking cellular LOXL3. This evidence concerns the gene BRAF and melanoma.